Arrowhead Pharmaceuticals宣布，其药物Redemplo® (Plozasiran)已获得欧盟委员会授予的上市许可，用于降低患有家族性乳糜微粒血症综合征（FCS）的成人患者的甘油三酯水平。FCS是一种罕见且严重的遗传性疾病，其特征是血液中甘油三酯水平极度升高，可导致危及生命的胰腺炎。该授权标志着Arrowhead Pharmaceuticals在罕见病治疗领域取得的重要进展，为欧洲的FCS患者提供了一种新的治疗选择。公司表示，将致力于尽快将这一创新疗法带给有需要的患者。
Arrowhead Pharmaceuticals宣布，其药物Redemplo® (Plozasiran)已获得欧盟委员会授予的上市许可，用于降低患有家族性乳糜微粒血症综合征（FCS）的成人患者的甘油三酯水平。FCS是一种罕见且严重的遗传性疾病，其特征是血液中甘油三酯水平极度升高，可导致危及生命的胰腺炎。该授权标志着Arrowhead Pharmaceuticals在罕见病治疗领域取得的重要进展，为欧洲的FCS患者提供了一种新的治疗选择。公司表示，将致力于尽快将这一创新疗法带给有需要的患者。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.